Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

Exclusion Criteria

• •1. Participation in another interventional clinical trial with investigational drug exposure within 30 days (or 5 half-lives, whichever is longer) prior to screening.
• •2. Phosphatidylethanol (PEth) value of ≥20 ng/mL measured at screening or clinically significant alcohol use within 1 year prior to screening.
• •3. FibroScan VCTE \>20 kPa, a baseline biopsy demonstrating fibrosis consistent with F4, or MRE \> 5 kPa.
• •4. Uncontrolled or clinically significant thyroid disease, including active hyperthyroidism or untreated hypothyroidism.
• •5. Evidence of active liver disease other than MASH.
• •6. History of liver transplantation for an inborn error of metabolism.
• •7. Evidence of hepatic impairment or decompensation at screening.
• •8. Steroid resistant rejection of the transplanted liver or kidney, or a history of a rejection treated with high dose steroid within 3 months of screening.
• •9. Chronic rejection or chronic plasma-cell hepatitis.
• •10. Significant post-transplant vascular or biliary complications.
• •11. Significant cardiovascular or cerebrovascular disease within 6 months prior to randomization.
• •12. Uncontrolled hypertension at screening or randomization.
• •13. Current hepatocellular carcinoma.
• •14. Known human immunodeficiency virus (HIV) infection or other clinically significant immunocompromised state.
• •15. Any serious medical condition with a life expectancy of less than 5 years.
• •16. Current substance abuse or drug addiction.
• •17. Significant psychiatric, cognitive, or social conditions that would interfere with study participation or compliance, in the Investigator's judgment.
• •18. Known hypersensitivity to study drug or any of its excipients.
• •19. Use of prohibited concomitant medications that may affect liver function, steatosis, thyroid function, or study outcomes, or unstable doses of allowed metabolic therapies prior to randomization.
• •20. Use of statins above protocol-allowed doses or unstable lipid-lowering therapy prior to randomization.
• •21. Contraindications to MRI, including implanted devices incompatible with MRI, severe claustrophobia, or inability to undergo MRI procedures.